Hummingbird Diagnostics is pioneering the development of novel miRNA-based liquid biopsy diagnostics for early disease detection of a broad range of indications. Our tests are performed using a liquid biopsy approach building on a track record of more than 7.000 clinical body fluid samples analyzed.
The Company possesses a high-quality miRNA whole blood database supported by a strong IP portfolio. Based on this platform, we have selected an initial set of highly disease-specific miRNA biomarkers with remarkable extracellular stability and are currently developing a portfolio of proprietary diagnostic tests.
Hummingbird’s lead program for the early diagnosis of Stage I/II lung cancer from blood samples is currently under clinical evaluation.
Our long-term goal is to enable partners, doctors and patients to detect serious and life-threatening conditions earlier, in a simpler and more accurate fashion and improve clinical outcomes through earlier intervention.
Hummingbird Diagnostics is using a liquid biopsy approach to generate miRNA biomarkers for diagnostics, drug discovery and safety.
The Company possesses a high-quality miRNA whole blood database supported by a strong IP portfolio.
Based on this platform, we are currently developing a portfolio of proprietary miRNA-based liquid biopsy diagnostics.
In addition, Hummingbird is offering its expertise and ISO-certified processes to 3rd parties who are interested in building diagnostics and therapeutics based on miRNAs from blood.
Hummingbird is an „Agilent Certified Services Provider” and accredited according to DIN EN ISO/IEC 17025:2005.
We are looking for partners in the field of diagnostic and drug development.
ENHANCED CLINICAL DRUG DEVELOPMENT
ACCESS TO IP PORTFOLIO
Hummingbird Diagnostics GmbH
Im Neuenheimer Feld 583
Phone: +49 6221 9143310
Fax: +49 6221 9143312
Get in contact with German companies in 3 easy steps! With one single question you can reach all relevant German Pavilion exhibitors of your selected industrial branch.
Click here if you notice an image that violates copyright or privacy rights.